MedTrace Logo

Bifocal & Atropine in Myopia (BAM) Study

NCT03312257 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2022-12-09

Study results available
· View outcomes & findings →

Summary

This study will test whether the combined treatment of 0.01% atropine and soft bifocal contact lens wear produces slower myopia progression and axial elongation compared to soft bifocal contact lenses alone in children ages 7 to 11 years old.

Conditions

  • Refractive Errors

Interventions

COMBINATION_PRODUCT

Multifocal D +2.50 add & 0.01% atropine

Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.

Sponsors & Collaborators

  • Jenny Jones

    lead OTHER

Principal Investigators

  • Juan Huang, PhD, OD · The Ohio State Univeristy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2020-06-30
Completion
2020-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03312257 on ClinicalTrials.gov